Few and far between have been product launches at Lundbeck the past few years, including the three years led by Deborah Dunsire, with the only new launch being that of Vyepti, which is – for Lundbeck – a relatively new area: migraine.
Lundbeck, under the leadership of Dunsire, has chosen this approach in particular because of the problems with the lack of launches. The company has suffered several failures with substances in late stages, of which idalopirdine and Lu AF35700 have been the most noteworthy. This is a statistic that Dunsire is set on changing.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.